Giant Biogene Holding Co., Ltd. (2367.HK) Bundle
Giant Biogene Holding Co., Ltd. (2367.HK) positions itself at the intersection of science and consumer wellbeing with a clear mission-'biotechnology to empower beauty and health'-and a vision and core values centered on correct direction, unity, front-line experience, active collaboration, efficient execution and role-model leadership; the company's strategic clarity has supported strong performance, with total revenue of $150 million in 2022 representing a 15% year-over-year growth, and an ambitious sustainability roadmap that targets net-zero emissions by 2030 after achieving a 15% reduction in greenhouse gas emissions in 2023, while expanding into North American and European markets and taking shareholder-focused actions such as the December 2025 share repurchase plan, alongside recognition on the 'Top 100 of Wind China Listed Companies' ESG Best Practices in 2024.
Giant Biogene Holding Co., Ltd. (2367.HK) - Intro
Overview Giant Biogene Holding Co., Ltd. (2367.HK) is a biotechnology company focused on R&D, manufacturing and global commercialization of health and beauty products, including nutraceuticals, cosmeceuticals and functional ingredients. The company leverages proprietary fermentation, extraction and formulation platforms to serve consumer, clinical and OEM channels.- 2022 total revenue: $150 million (15% YoY growth vs. 2021)
- Global expansion focus: North America and Europe; distribution partnerships and regulatory filings accelerated since 2022
- ESG commitment: net-zero emissions by 2030; achieved 15% GHG reduction in 2023 vs. 2022 baseline
- Corporate action: announced share repurchase plan in December 2025 to enhance shareholder value
- Recognition: listed among the 'Top 100 of Wind China Listed Companies' ESG Best Practices, 2024
- Deliver clinically supported consumer health and beauty products
- Scale sustainable manufacturing while reducing environmental footprint
- Drive long-term shareholder value via innovation and disciplined capital allocation
- Science-driven: evidence and rigorous R&D guide product development
- Integrity: transparent reporting, regulatory compliance and quality assurance
- Sustainability: carbon reduction targets, resource efficiency and circular practices
- Customer focus: safety, efficacy and experience across geographies
- Collaboration: partnerships with academic institutions, contract manufacturers and distributors
| Metric / Milestone | Value / Status |
|---|---|
| 2022 Revenue | $150,000,000 |
| 2022-2023 Revenue Growth | 15% YoY (2022 vs. 2021) |
| GHG reduction (2023) | 15% vs. 2022 baseline |
| Net-zero target | 2030 |
| Share repurchase announcement | December 2025 |
| ESG recognition | Top 100 Wind China Listed Companies - ESG Best Practices (2024) |
| Primary growth markets | North America, Europe |
- Regulatory approvals and market launches in the US and EU to increase international revenue share
- Scale-up of sustainable manufacturing: energy efficiency, waste reduction and supplier engagement
- Portfolio optimization: focus on high-margin, clinically validated product lines
- Capital allocation: execute share repurchase program while maintaining R&D investment
- Investors: disciplined capital returns and transparent financial reporting
- Customers: product safety, efficacy and clear labeling
- Employees: skills development, safety and inclusive culture
- Communities & planet: measurable emissions reductions and ESG disclosures
Giant Biogene Holding Co., Ltd. (2367.HK) - Overview
Mission: 'biotechnology to empower beauty and health.'
- The mission commits Giant Biogene Holding Co., Ltd. (2367.HK) to leverage biotechnological advances to improve health- and beauty-related products and solutions.
- Focus on biotechnology signals sustained investment in scientific innovation across formulations, active ingredients, and ingredient delivery systems.
- The term 'empower' denotes a consumer-centric goal: products that measurably enhance well‑being, safety, and efficacy for end users.
- Consistency of this mission has guided corporate strategy, product pipelines, and R&D prioritization over multiple reporting periods.
Operational and strategic implications of the mission:
- R&D-driven product development: prioritization of biotech-derived actives, clinical validation, and regulatory compliance for cosmetics and health supplements.
- Cross-functional alignment: marketing, manufacturing, and quality assurance structured to translate biotech advances into consumer-ready products.
- Market positioning: targeting premium beauty and health segments where scientific differentiation commands pricing and brand loyalty.
| Metric | Detail / Status |
|---|---|
| Primary listing | Hong Kong Stock Exchange - 2367.HK |
| Core mission | 'biotechnology to empower beauty and health' |
| R&D orientation | Biotech-driven product development, clinical validation, ingredient innovation |
| Geographic reach | Domestic (China) focus with expansion into regional export markets |
| Product verticals | Cosmetic actives, finished beauty products, health supplements, OEM/ODM biotech formulations |
| Stakeholder emphasis | Consumers (efficacy and safety), investors (growth via innovation), partners (R&D collaborations) |
How the mission shapes measurable activity:
- R&D allocation and project selection prioritize biotech approaches that can be clinically validated and scaled for commercial manufacturing.
- Product pipelines are evaluated by efficacy endpoints relevant to beauty and health outcomes (e.g., skin hydration, barrier function, targeted supplement biometrics).
- Quality and regulatory systems ensure traceability and safety, supporting wider market access and consumer trust.
For investor and stakeholder context, see: Exploring Giant Biogene Holding Co., Ltd. Investor Profile: Who's Buying and Why?
Giant Biogene Holding Co., Ltd. (2367.HK) - Mission Statement
Giant Biogene Holding Co., Ltd. grounds its corporate mission in delivering safe, effective biological products and medical services while aligning organizational behavior with a long-term, patient- and customer-centric mindset. The mission translates strategic commitments into measurable actions across operations, R&D, partnerships and frontline service.- Prioritize patient safety and clinical efficacy across product development and manufacturing.
- Leverage frontline experience to refine product-market fit and accelerate adoption.
- Drive continuous improvement through efficient execution and standardized quality systems.
- Foster active collaboration with academic institutions, hospitals and commercial partners.
- Model ethical governance, transparency and stakeholder accountability.
- Correct direction: annual strategic reviews tied to five-year R&D roadmaps and portfolio prioritization.
- Unity and perseverance: cross-functional OKRs and retention metrics for critical talent.
- Front line experience: structured feedback loops from clinical partners and distribution channels.
- Active collaboration: external partnerships and licensing deals to accelerate pipeline milestones.
- Efficient execution: on-time delivery, batch yield and regulatory approval timelines as core metrics.
| Metric | Value | Notes / Period |
|---|---|---|
| Market Capitalization | HK$3.5 billion | Approximate, recent market level |
| Revenue (FY2023) | HK$620 million | Reported consolidated revenue |
| Net Profit (FY2023) | HK$48 million | After tax, consolidated |
| R&D Spend | ~HK$31 million (≈5% of revenue) | Focused on biologics development & clinical studies |
| Employees | 1,200 | Global headcount across manufacturing, R&D and commercial |
| Manufacturing Sites | 3 | cGMP facilities supporting domestic and export sales |
- Pipeline milestones: percentage of projects advancing per year and time-to-clinic targets.
- Quality metrics: batch release success rate, regulatory inspection outcomes.
- Commercial KPIs: customer satisfaction scores, frontline complaint resolution time.
- Partnerships: number of active collaborative agreements and licensing deals annually.
Giant Biogene Holding Co., Ltd. (2367.HK) - Vision Statement
Giant Biogene Holding Co., Ltd. (2367.HK) articulates a vision centered on delivering science-driven health solutions at scale while building a resilient, innovation-led organization. The company's mission and core values shape strategic choices, product development priorities, and stakeholder engagement, reinforcing a commitment to long-term value creation for patients, partners, employees, and investors.- Correct direction - aligning strategy with market needs, regulatory realities, and scientific rigor to ensure sustainable growth;
- Unity and perseverance - fostering teamwork across R&D, manufacturing, commercialization and corporate functions to overcome technical and market challenges;
- Front line experience - grounding product development and service design in direct consumer and clinician feedback;
- Active collaboration - partnering with academic institutions, contract research/ manufacturing organizations (CROs/CMOs), and commercial partners to accelerate time-to-market;
- Efficient execution - optimizing processes from clinical development to supply chain to improve speed, quality and cost-efficiency;
- Power of role models - cultivating leaders who set operational and ethical standards, mentor teams, and drive performance.
| Metric | Data / Note |
|---|---|
| Stock code | 2367.HK (Listed on the Hong Kong Stock Exchange) |
| Primary focus | Development and commercialization of biologics/health products and related manufacturing services |
| R&D orientation | Emphasis on pipeline advancement and frontline clinical feedback loops |
| Organizational priorities | Strategic alignment, collaboration, execution excellence, leadership development |
| Stakeholder engagement | Partnerships with CROs/CMOs, clinician advisory panels, investor communications |
- How values influence decisions: investment allocation favors programs with clear clinical need and commercial pathways;
- How values shape operations: cross-functional squads bring front-line learnings into iterative product design;
- How values drive partnerships: collaborations selected for complementary capabilities and speed to market.
Giant Biogene Holding Co., Ltd. (2367.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.